Joint venture to benefit presbyopia patients

Article

Technolas Perfect Vision is the new company name for the joint venture between Bausch & Lomb and 20/10 Perfect Vision AG that will focus on laser vision correction.

Technolas Perfect Vision is the new company name for the joint venture between Bausch & Lomb and 20/10 Perfect Vision AG that will focus on laser vision correction.

The business will initially concentrate on treatments for presbyopia and aims to provide clinicians with advanced excimer and femtosecond laser technology. One of its new procedures is INTRACOR, an intrastromal treatment, which carries the CE mark for treatment of presbyopic hypreopes.

Dr Kristian Hohla, Technolas's new CEO sees this as potentially huge: "These are breakthrough technologies, transforming the lifestyle of presbyopia sufferers and providing clinicians with a wonderful opportunity to attract a stream of new patients to their refractive practices."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Related Content
Logos for Topcon Healthcare (left, black and purple) and Intelligent Retinal Imaging Systems (IRIS, right, blue and green). Concept image for diabetic eye disease retina screening company merger. Image courtesy of Topcon Healthcare.

Topcon expands AI portfolio with Intelligent Retinal Imaging Systems acquisition

Hattie Hayes
July 31st 2025
Article

The IRIS is a cloud-based model that supports artificial intelligence-assisted diabetic retinopathy screening

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Exonate announces CLEAR-DE trial for EXN407

Exonate announces CLEAR-DE trial for EXN407

Kassi Filkins
July 30th 2025
Article

Exonate initiates a phase 2b trial for EXN407, a groundbreaking eye drop treatment for diabetic retinopathy

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The retina undergoing fundus imaging. Concept image for retinal imgaging, OCT, CA, cardiac angiography, optical coherence tomography and biomarkers. Image credit: ©Panama – stock.adobe.com

Biomarkers of microvascular retinal perfusion indicating coronary heart disease

Lynda Charters
July 29th 2025
Article

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography

A photo of the European Medicines Agency (EMA) headquarters. Concept image for Alteogen aflibercept biosimilar approval, Committee for Medicinal Products for Human Use CHMP positive opinion for EYLUXVI. Image credit: ©Ogulcan Aksoy - SCA – stock.adobe.com

Alteogen receives positive CHMP opinion for aflibercept biosimilar EYLUXVI

Martin David Harp
July 28th 2025
Article

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”

© 2025 MJH Life Sciences

All rights reserved.